Be sure to check our sister interview main ratings news website

Hardman & Co Investor Forum 26th February 2019

Last week we were delighted to host our 15th Investor Forum at the offices of DAC Beachcroft. We welcomed 4 interesting companies to present to an audience of 60 sophisticated investors. The audience had the opportunity to learn more about investing in clean energy, a dividend paying gold miner, and two distinct health care companies at different commercial stages.

Read in Full
Click to view all articles for the EPIC: , ,
Or click to view the full company profile:
Facebook
X
LinkedIn
Hardman & Co

More articles like this

Hardman & Co

Anglo Asian Mining at a key moment in its evolution (VIDEO)

31st May 2023

Anglo Asian Mining (LON:AAZ) is the topic of conversation when Paul Mylchreest, Analyst at Hardman & Co joins DirectorsTalk Interviews. Paul gives us an overview of Anglo Asian Mining, outlines for us the strategic transformation that Anglo

Hardman & Co

Shield Therapeutics: Positioned for growth and profitability

13th January 2023

Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been

Hardman & Co

Shield Therapeutics: Accrufer momentum building

16th September 2022

Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following launch of Accrufer® in the US, in July 2021, the

Hardman & Co

Shield Therapeutics: PBMs have bought in to Accrufer

4th March 2022

Shield Therapeutics plc (LON:STX) is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Following the US launch of Accrufer® in July 2021, the

Hardman & Co

Shield Therapeutics: Focused on US market penetration

23rd August 2021

Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Accrufer® has just been launched in the US by

Hardman & Co

Shield Therapeutics: Accrufer® launch on schedule

26th May 2021

Shield Therapeutics plc (LON:STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID). Feraccru®/Accrufer® has been approved by the regulators in both

Gresham House plc

Gresham House Energy Storage Fund NAV up 74% to £358.9m

28th April 2021

Gresham House Energy Storage Fund plc (LON:GRID), the UK’s largest utility-scale battery energy storage fund, has announced its second set of annual results since the IPO in November 2018. This covers the 12 months ended 31

Gresham House plc

Gresham House strengthens Institutional Business team

26th April 2021

Gresham House plc, the specialist alternative asset manager, has appointed James Lindsay as Head of Institutional Business. James joins from MFS Investment Management where he was Managing Director and Head of Sales, leading its UK institutional

© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.